Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01644877 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
A Phase 2 study, sponsored by Ansun Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT01644877 is a Phase 2 study that has completed, run by Ansun Biopharma. The registered enrollment target is 111 participants.
The verdict
NCT01644877, a Phase 2 study, has completed, sponsored by Ansun Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
This protocol will seek to enroll immunocompromised patients who are on supplemental oxygen and diagnosed with a parainfluenza infection.
Interventions
- DRUG DAS181 dry powder, formulation F02
- DRUG Lactose Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01644877
The ClinicalTrials.gov registry entry for NCT01644877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ansun Biopharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DAS181 dry powder, formulation F02 is the first listed.
NCT01644877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01644877 about?
NCT01644877 is a clinical study titled "A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen". This protocol will seek to enroll immunocompromised patients who are on supplemental oxygen and diagnosed with a parainfluenza infection.
What is the current status of trial NCT01644877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2014-03. Estimated completion is 2016-12-15.
What interventions are being tested in trial NCT01644877?
The interventions under investigation include: DAS181 dry powder, formulation F02 (DRUG), Lactose Placebo (DRUG).
Who is sponsoring clinical trial NCT01644877?
This trial is sponsored by Ansun Biopharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.